Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p190
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 190/191)
Character Range: 11371985–11381336

rejection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Compliance with Authority Required procedures - Streamlined Authority Code 9914
                                                                                                                                                                                                                               Management (initiation, stabilisation and review of therapy)
                                                                                                                                                                                                                               Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND
                                                                                                                                                                                                                               The treatment must be under the supervision and direction of a transplant unit.
C9919               P9919          CN9919           Sodium phenylbutyrate                                                                                                                                                      Urea cycle disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures - Streamlined Authority Code 9919
                                                                                                                                                                                                                               Continuing treatment
                                                                                                                                                                                                                               Patient must have previously received PBS-subsidised treatment with this drug for this condition.
C9981               P9981          CN9981           Dolutegravir with abacavir and lamivudine                                                                                                                                  HIV infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 9981
                                                                                                                                                                                                                               Initial treatment
                                                                                                                                                                                                                               Patient must be antiretroviral treatment naive.
C9987               P9987          CN9987           Dolutegravir with lamivudine                                                                                                                                               HIV infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 9987
                                                                                                                                                                                                                               Initial treatment
                                                                                                                                                                                                                               Patient must be antiretroviral treatment naive; AND
                                                                                                                                                                                                                               Patient must not have suspected resistance to either antiretroviral component.
C9993               P9993          CN9993           Sodium phenylbutyrate                                                                                                                                                      Urea cycle disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures - Streamlined Authority Code 9993
                                                                                                                                                                                                                               Initial treatment
                                                                                                                                                                                                                               Patient must have elevated ammonia levels that are not controlled with diet alone and other adjunct care alone.

National Health (Listing of Pharmaceutical Benefits) Instrument 2024

PB 26 of 2024
made under sections 84AF, 84AK, 85, 85A and 88 of the

National Health Act 1953

Compilation No. 10

Compilation date: 1 February 2025

                Includes amendments: F2025L00062

This compilation is in 10 volumes

Volume 1: sections 1–24 and Schedule 1 (Part 1: A–C)
Volume 2: Schedule 1 (Part 1: D–K)
Volume 3: Schedule 1 (Part 1: L–P)
Volume 4: Schedule 1 (Part 1: Q–Z, Part 2), Schedules 2 and 3
Volume 5: Schedule 4 (Part 1: C4076–C9993)
Volume 6: Schedule 4 (Part 1: C10020–C12999)
Volume 7: Schedule 4 (Part 1: C13006–C13925)
Volume 8: Schedule 4 (Part 1: C13927–C14567)
Volume 9: Schedule 4 (Part 1: C14568–C16290, Part 2)
Volume 10: Schedules 5, 6 and Endnotes

Each volume has its own contents

About this compilation

This compilation

This is a compilation of the National Health (Listing of Pharmaceutical Benefits) Instrument 2024 that shows the text of the law as amended and in force on 1 February 2025 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a